deferiprone has been researched along with Cirrhosis, Liver in 20 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The role of the orally active iron (Fe) chelator deferiprone in the treatment of beta-thalassemia remains a controversial subject." | 8.81 | The controversial role of deferiprone in the treatment of thalassemia. ( Richardson, DR, 2001) |
| "Patients with thalassemia major require lifelong chelation therapy to prevent iron-induced organ damage." | 6.70 | Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. ( Cohen, AR; Dhillon, AP; Galanello, R; Gamberini, MR; Guido, M; Piga, A; Schwartz, E; Sweeney, G; Wanless, IR, 2002) |
| "Deferiprone is an orally active iron-chelating agent that is being evaluated as a treatment for iron overload in thalassemia major." | 5.08 | Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. ( Brittenham, GM; Burt, AD; Cameron, RG; Fleming, KA; McClelland, RA; McLaren, CE; Olivieri, NF; Templeton, DM, 1998) |
| "The role of the orally active iron (Fe) chelator deferiprone in the treatment of beta-thalassemia remains a controversial subject." | 4.81 | The controversial role of deferiprone in the treatment of thalassemia. ( Richardson, DR, 2001) |
| "Deferiprone (L1) is an orally active iron-chelation agent that is being evaluated as a treatment for iron overload in thalassemia major." | 3.73 | Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. ( Peng, CT; Tsai, CH; Wu, KH; Wu, SF, 2006) |
| "Patients with thalassemia major require lifelong chelation therapy to prevent iron-induced organ damage." | 2.70 | Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. ( Cohen, AR; Dhillon, AP; Galanello, R; Gamberini, MR; Guido, M; Piga, A; Schwartz, E; Sweeney, G; Wanless, IR, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (40.00) | 18.2507 |
| 2000's | 11 (55.00) | 29.6817 |
| 2010's | 1 (5.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dessì, C | 1 |
| Leoni, G | 1 |
| Moi, P | 1 |
| Danjou, F | 1 |
| Follesa, I | 1 |
| Foschini, ML | 1 |
| Morittu, M | 1 |
| Zappu, A | 1 |
| Defraia, E | 1 |
| Bina, P | 1 |
| Cunico, A | 1 |
| Civolani, A | 1 |
| Podda, RA | 1 |
| Origa, R | 1 |
| Wanless, IR | 1 |
| Sweeney, G | 1 |
| Dhillon, AP | 1 |
| Guido, M | 1 |
| Piga, A | 2 |
| Galanello, R | 1 |
| Gamberini, MR | 1 |
| Schwartz, E | 1 |
| Cohen, AR | 1 |
| Brittenham, GM | 2 |
| Nathan, DG | 2 |
| Olivieri, NF | 2 |
| Porter, JB | 1 |
| Pippard, M | 1 |
| Vichinsky, EP | 1 |
| Weatherall, DJ | 3 |
| Downie, J | 1 |
| Baird, P | 1 |
| Thompson, J | 1 |
| Viens, AM | 1 |
| Savulescu, J | 1 |
| Roggero, S | 1 |
| Vinciguerra, T | 1 |
| Sacchetti, L | 1 |
| Gallo, V | 1 |
| Longo, F | 1 |
| Meo, A | 1 |
| Ruggeri, A | 1 |
| La Rosa, MA | 1 |
| Zanghì, L | 1 |
| Morabito, N | 1 |
| Duca, L | 1 |
| Chen, AC | 1 |
| Peng, CT | 2 |
| Wu, SF | 2 |
| Wu, KH | 2 |
| Chiang, IP | 1 |
| Tsai, CH | 2 |
| Töndury, P | 2 |
| Zimmermann, A | 1 |
| Nielsen, P | 1 |
| Hirt, A | 1 |
| McLaren, CE | 1 |
| Templeton, DM | 1 |
| Cameron, RG | 1 |
| McClelland, RA | 1 |
| Burt, AD | 1 |
| Fleming, KA | 1 |
| Kowdley, KV | 1 |
| Kaplan, MM | 1 |
| Tricta, F | 1 |
| Spino, M | 1 |
| Callea, F | 1 |
| Stella, M | 1 |
| Pinzello, G | 1 |
| Maggio, A | 1 |
| Wonke, B | 1 |
| Telfer, P | 1 |
| Hoffbrand, AV | 1 |
| Pippard, MJ | 1 |
| Kontoghiorghes, GJ | 1 |
| Agarwal, MB | 1 |
| Marx, JJ | 1 |
| Richardson, DR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Retrospective and Prospective Multicenter Study Using Deferiprone (L1) Alone or in Combination With Desferrioxamine for the Treatment of Iron Overload in Transfusion-dependent Patients[NCT00349453] | Phase 2 | 24 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for deferiprone and Cirrhosis, Liver
| Article | Year |
|---|---|
Deferiprone: New insight.
Topics: Agranulocytosis; Cardiomyopathies; Clinical Trials as Topic; Deferiprone; Deferoxamine; Follow-Up St | 2005 |
Oral iron chelation therapy for thalassaemia: an uncertain scene.
Topics: beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron | 2000 |
The controversial role of deferiprone in the treatment of thalassemia.
Topics: Agranulocytosis; Arthralgia; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Comb | 2001 |
2 trials available for deferiprone and Cirrhosis, Liver
| Article | Year |
|---|---|
Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia.
Topics: Adolescent; Adult; beta-Thalassemia; Biopsy; Blood Transfusion; Child; Deferiprone; Female; Humans; | 2002 |
Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Biopsy; Child; Deferiprone; Deferoxamine; Disease Progression; | 1998 |
15 other studies available for deferiprone and Cirrhosis, Liver
| Article | Year |
|---|---|
Thalassemia major between liver and heart: Where we are now.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Cohort Studies; Deferiprone; Deferoxam | 2015 |
Deferiprone and hepatic fibrosis.
Topics: Deferiprone; Humans; Iron Overload; Liver Cirrhosis; Pyridones | 2003 |
Industry and the academy: conflicts of interest in contemporary health research.
Topics: Biomedical Research; Clinical Trials as Topic; Conflict of Interest; Deferiprone; Drug Industry; Hos | 2002 |
Introduction to The Olivieri symposium.
Topics: beta-Thalassemia; Bioethical Issues; Blood Transfusion; Canada; Clinical Trials as Topic; Deferipron | 2004 |
Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation.
Topics: Adolescent; Anemia, Sideroblastic; Biomarkers; Bone Marrow Transplantation; Chelation Therapy; Combi | 2006 |
Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia.
Topics: Adolescent; Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Chelatio | 2006 |
Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Topics: Adolescent; Adult; Alanine Transaminase; beta-Thalassemia; Biomarkers; Biopsy; Chelation Therapy; Ch | 2006 |
Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chronic Disease; Deferiprone; Ferritins; Hepatitis C; Humans; I | 1998 |
Iron-chelation therapy with oral deferiprone--toxicity or lack of efficacy?
Topics: Administration, Oral; beta-Thalassemia; Biopsy; Deferiprone; Humans; Iron; Iron Overload; Liver; Liv | 1998 |
Iron chelation with oral deferiprone in patients with thalassemia.
Topics: beta-Thalassemia; Biopsy; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Liver Cirrhosis | 1998 |
Iron chelation with oral deferiprone in patients with thalassemia.
Topics: beta-Thalassemia; Biopsy; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Liver; Liver Ci | 1998 |
Iron chelation with oral deferiprone in patients with thalassemia.
Topics: beta-Thalassemia; Biopsy; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Liver; Liver Ci | 1998 |
Iron chelation with oral deferiprone in patients with thalassemia.
Topics: beta-Thalassemia; Biopsy; Deferiprone; Deferoxamine; Ferritins; Humans; Iron Chelating Agents; Iron | 1998 |
Iron chelation with oral deferiprone in patients with thalassemia.
Topics: beta-Thalassemia; Deferiprone; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Liver Cirr | 1998 |
Deferiprone or fatal iron toxic effects?
Topics: Deferiprone; Humans; Iron Chelating Agents; Liver Cirrhosis; Pyridones; Thalassemia | 2001 |